Want to see SG:H02 full AI Analyst Report?
H02 Stock Chart & Stats
S$16.29
S$0.06(0.53%)
At close: 4:00 PM EST
S$16.29
S$0.06(0.53%)
Day’s Range― - ―
52-Week RangeS$12.07 - S$18.27
Previous CloseN/A
Volume149.20K
Average Volume (3M)144.52K
Market Cap
S$3.53B
Enterprise ValueS$2.83B
Total Cash (Recent Filing)S$834.71M
Total Debt (Recent Filing)S$44.27M
Price to Earnings (P/E)13.1
Beta0.72
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield8.96%
Share Statistics
EPS (TTM)1.20
Shares Outstanding221,368,180
10 Day Avg. Volume160,760
30 Day Avg. Volume144,516
Financial Highlights & Ratios
PEG Ratio0.79
Price to Book (P/B)0.81
Price to Sales (P/S)15.10
P/FCF Ratio12.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.25
Revenue Forecast (FY)S$244.68M
Bulls Say, Bears Say
Bulls Say
Very Strong Balance SheetExtremely low leverage and steady equity growth give the company durable financial flexibility. Over the next 2-6 months this supports capacity to fund operations, dividends, and opportunistic investments without refinancing risk, reducing downside in economic stress.
Improved 2025 Cash GenerationA step-up in operating and free cash flow that closely matched net income in 2025 enhances the company's ability to self-fund capex, pay distributions, and de-risk operations. If sustained, stronger cash conversion materially improves long-term financial resilience.
Diversified, Durable Revenue StreamsA strong consumer brand (Tiger Balm) plus recurring rental income and leisure operations create diversification across product and real-estate cash flows. This mix smooths revenue cyclicality and supports steady cash generation over multi-quarter horizons.
Bears Say
2025 Revenue DeclineA notable top-line decline in 2025 weakens the base for sustainable earnings and could pressure margins if fixed costs remain. Over the coming months, continued revenue softness would constrain organic growth, reinvestment, and dividend sustainability.
Earnings Quality ConcernsMargins inflated by non-operating items reduce confidence that reported profits are repeatable. For durable forecasting and dividend planning, reliance on one-off gains increases volatility in shareholder returns and complicates assessment of underlying operating performance.
Historically Lumpy Cash ConversionPast variability in converting accounting earnings to cash makes near-term free cash flow uncertain despite 2025 improvement. This raises structural planning risk for capex, rent rollovers, and distributions, and increases sensitivity to working capital swings.
Haw Par News
H02 FAQ
What was Haw Par Corporation Limited’s price range in the past 12 months?
Haw Par Corporation Limited lowest share price was S$12.07 and its highest was S$18.27 in the past 12 months.
What is Haw Par Corporation Limited’s market cap?
Haw Par Corporation Limited’s market cap is S$3.53B.
When is Haw Par Corporation Limited’s upcoming earnings report date?
Haw Par Corporation Limited’s upcoming earnings report date is Aug 19, 2026 which is in 44 days.
How were Haw Par Corporation Limited’s earnings last quarter?
Haw Par Corporation Limited released its earnings results on Feb 27, 2026. The company reported S$0.548 earnings per share for the quarter, beating the consensus estimate of N/A by S$0.548.
Is Haw Par Corporation Limited overvalued?
According to Wall Street analysts Haw Par Corporation Limited’s price is currently Overvalued.
Does Haw Par Corporation Limited pay dividends?
Haw Par Corporation Limited pays a Annually dividend of S$0.2 which represents an annual dividend yield of 8.96%. See more information on Haw Par Corporation Limited dividends here
What is Haw Par Corporation Limited’s EPS estimate?
Haw Par Corporation Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Haw Par Corporation Limited have?
Haw Par Corporation Limited has 221,368,180 shares outstanding.
What happened to Haw Par Corporation Limited’s price movement after its last earnings report?
Haw Par Corporation Limited reported an EPS of S$0.548 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.889%.
Which hedge fund is a major shareholder of Haw Par Corporation Limited?
Currently, no hedge funds are holding shares in SG:H02
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Haw Par Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.41%
12-Months-Change
Fundamentals
Return on Equity
6.34%
Trailing 12-Months
Asset Growth
9.58%
Trailing 12-Months
Company Description
Haw Par Corporation Limited
Established in Singapore in 1969, Haw Par Corporation Limited specializes in the manufacturing, marketing, and global trade of healthcare products, serving markets in Singapore, ASEAN countries, other Asian regions, and beyond. The company's business activities are structured into three main segments: Healthcare, Investments, and Others. Its Healthcare segment primarily produces and distributes topical pain relief solutions, prominently featuring the Tiger Balm and Kwan Loong brands. The Investments segment focuses on acquiring publicly traded securities. Additionally, Haw Par owns and leases out a diverse portfolio of investment properties, comprising 45,324 square meters of commercial and industrial real estate across Singapore and Malaysia. The corporation also offers family and tourist-oriented leisure experiences, notably through oceanariums. Furthermore, it provides leasing services for land, buildings, and office spaces, in addition to offering management support.
Technical Analysis
Raffles Medical Group
―
Thomson Medical Group Ltd.
―
Hyphens Pharma International Ltd.
―
ISEC Healthcare Ltd
―
Medtecs International Corporation Ltd.
―
Options Prices
Currently, No data available
---



